Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Function Tests

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Respiratory Assessment: Purpose and Indications

Respiratory Assessment: Purpose and Indications

Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood Phenylalanine Control in Paediatric and Adult Centres in the UK: Data from 2012-2018.

Nutrients·2026

Same author

How Well Is Blood Phenylalanine Controlled in Maternal PKU in Europe? Results from 102 Pregnancies.

Nutrients·2026

Same author

Perspective of the European Cystic Fibrosis Society on Improving Global Cystic Fibrosis Care.

Pediatric pulmonology·2026

Same author

Bovine alkaline phosphatase in health and disease: A bibliometric and narrative review.

Veterinary and animal science·2026

Same author

Assessment of Ocular Surface Pathogen Susceptibility to Ultraviolet-C (UVC) Light Treatment With a Novel Prototype Device-An In Vitro Study.

Veterinary ophthalmology·2026

Same author

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2026 Annual Pediatric Heart Transplantation Report, Trends and Post-transplant Outcomes by Recipient Sex.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Search research articles

Related Experiment Video

Updated: Sep 9, 2025

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

Spirometry thresholds for clinical trial eligibility: time for urgent re-evaluation.

Idan Bokobza^1,2,3, Melanie Le Sayec^2,4, Cara Bossley^2,4

¹National Heart and Lung Institute, Imperial College London, London, UK.

|September 4, 2025

Summary

Switching spirometry equations for clinical trial eligibility impacts patient access. The new GLI-Global equations may exclude over 700 individuals, necessitating a review of trial thresholds for equitable access.

Keywords:

Cystic Fibrosis Respiratory Measurement

More Related Videos

Conducting Respiratory Oscillometry in an Outpatient Setting

Conducting Respiratory Oscillometry in an Outpatient Setting

Published on: April 8, 2022

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Sep 9, 2025

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

Conducting Respiratory Oscillometry in an Outpatient Setting

Conducting Respiratory Oscillometry in an Outpatient Setting

Published on: April 8, 2022

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

Area of Science:

Pulmonary Medicine
Clinical Trial Design
Spirometry Standards

Background:

Respiratory clinical trials commonly use per cent-predicted forced expiratory volume in 1 second (ppFEV1) thresholds between 40% and 90% based on ethnicity-dependent GLI-2012 equations.
International guidelines now recommend newer, 'race-neutral' GLI-Global spirometry reference equations.

Purpose of the Study:

To quantify the impact of transitioning from GLI-2012 to GLI-Global equations on respiratory clinical trial eligibility.
To assess the effect on patient access within the UK Cystic Fibrosis Registry.

Main Methods:

Analysis of spirometry data from the UK Cystic Fibrosis Registry (n=8182).
Comparison of ppFEV1 values calculated using GLI-2012 and GLI-Global equations.
Modeling the effect of a 90% ppFEV1 eligibility threshold under the new equations.

Main Results:

The shift to GLI-Global equations, particularly with a 90% ppFEV1 upper limit, would render over 700 individuals newly ineligible.
This change highlights potential disparities in trial access based on spirometry equation choice.

Conclusions:

Urgent review of fixed ppFEV1 thresholds in clinical trial eligibility is required with the adoption of GLI-Global equations.
An initial recommendation is to widen the ppFEV1 eligibility range to 30-95% to ensure equitable access across ethnicities.
A broader re-evaluation of fixed ppFEV1 limits for trial participation is necessary to promote inclusivity.